Furthermore, our more recent studies have demonstrated that Atp6i can be targeted to prevent both bone loss and inflammation in mouse models of periodontal disease8 and periapical disease,9 implicating Atp6i as a key target in oral disease through its important role in osteoclast activity. Here, TCIRG1 is linked to mouth disorder.